🟢 Atea Pharmaceuticals is trading 5% up today after BEM/RZR met Phase 3 HCV endpoint

Atea Pharmaceuticals is trading 5.14% up now at $5.32 after investors digested August 12, 2026, earnings and encouraging hepatitis C trial data.

• Reported a narrower-than-expected $0.41-per-share loss versus $0.56 expected.
• BEM/RZR met the C-BEYOND Phase 3 endpoint and demonstrated non-inferiority to standard treatment.
• Reported $219.5 million in cash and investments, supporting operations through 2027.